^
BIOMARKER:

TNFRSF17 deletion

i
Other names: TNFRSF17, TNF Receptor Superfamily Member 17, Tumor Necrosis Factor Receptor Superfamily Member 17, B-Cell Maturation Protein, BCMA, Tumor Necrosis Factor Receptor Superfamily, Member 17, B Cell Maturation Antigen, B-Cell Maturation Factor, CD269 Antigen, TNFRSF13A, CD269
Entrez ID:
Related biomarkers:
5ms
We identified selection of a clone with homozygous deletion of TNFRSF17 (BCMA) as the underlying mechanism of immune escape. Furthermore, we found heterozygous TNFRSF17 loss or monosomy 16 in 37 out of 168 patients with MM, including 28 out of 33 patients with hyperhaploid MM who had not been previously treated with BCMA-targeting therapies, suggesting that heterozygous TNFRSF17 deletion at baseline could theoretically be a risk factor for BCMA loss after immunotherapy.
Clinical • Clinical Trial,Phase II • Journal • CAR T-Cell Therapy • IO biomarker
|
TNFRSF17 (TNF Receptor Superfamily Member 17)
|
TNFRSF17 deletion